Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Takeda Pharmaceutical Co ( (JP:4502) ).
Takeda Pharmaceutical Co. announced its plan to withdraw a previous Shelf Registration Statement and file a new one in Japan to issue new shares or dispose of treasury shares. This move is aimed at supporting the company’s Long Term Incentive Plan (LTIP) for employees. The scheduled issue amount is up to JPY 220 billion, with an expected share dilution of around 1.1% for the fiscal year ending March 31, 2026. This strategic decision allows Takeda to manage its equity more flexibly and aligns with its ongoing efforts to incentivize its workforce.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda is a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, focused on creating better health and a brighter future. It specializes in core therapeutic areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. With a commitment to patients, people, and the planet, Takeda operates in approximately 80 countries and regions.
YTD Price Performance: 5.44%
Average Trading Volume: 5,309,542
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen6837.5B
See more data about 4502 stock on TipRanks’ Stock Analysis page.